Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20837081 | 0.86 | HRH3 (0.41) | HRH3MAPTALDH1A1L3MBTL1POLB | |
| SCHEMBL20837328 | 0.80 | POLB (0.42) | HRH3MAPTALDH1A1L3MBTL1POLB | |
| SCHEMBL1596887 | 0.79 | POLB (0.42) | HRH3MAPTL3MBTL1POLBKMT2A | |
| SCHEMBL2679802 | 0.79 | POLB (0.42) | HRH3MAPTL3MBTL1POLBKMT2A | |
| SCHEMBL1596883 | 0.79 | POLB (0.42) | HRH3MAPTL3MBTL1POLBKMT2A | |
| Hydrochloric Acid SCHEMBL20570928 | 0.78 | POLB (0.41) | HRH3MAPTL3MBTL1POLBKMT2A | |
| Hydrochloric Acid SCHEMBL30223574 | 0.78 | POLB (0.41) | HRH3MAPTALDH1A1L3MBTL1POLB | |
| SCHEMBL17366260 | 0.78 | CHRM2 (0.45) | L3MBTL1POLB | |
| SCHEMBL29116530 | 0.77 | TSHR (0.40) | HRH3MAPTALDH1A1L3MBTL1POLB | |
| SCHEMBL28579495 | 0.76 | HRH3 (0.45) | HRH3MAPTALDH1A1L3MBTL1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10738056-B2 | Pyrazolopyrimidinone compounds and uses thereof | ADURO BIOTECH INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-20190119285-A1 | PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF | CHINOOK THERAPEUTICS, INC. | 2019-04-25 | — | — | US | disclosed |
| WO-2019055750-A1 | PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF | Aduro Biotech, Inc. (US) | 2019-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10738056-B2 | Pyrazolopyrimidinone compounds and uses thereof | NLRP3, NLRP1, P2RX7 | HRH3 1045/4885MAPT 214/4885ALDH1A1 1246/4885 |
| US-20190119285-A1 | PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF | NLRP3, NLRP1, P2RX7 | HRH3 1045/4885MAPT 214/4885ALDH1A1 1246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.